Risk Stratification for Late-Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV-Specific Cell-Mediated Immunity. (PubMed, Transpl Infect Dis) - Jun 11, 2026 - "Our findings suggest that D-/R+ CMV serology and the presence of GVHD, combined with CMV-QTF, may be considered as a useful tool to predict which patients receiving LTV might benefit from an extension of prophylaxis up to 200 days after HSCT."
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Transplantation
|
|
Alessandro Busca; Carolina Secreto; Chiara Dellacasa; Cristina Costa; Francesca Bassi; Francesca Sidoti; Francesco Giuseppe De Rosa; Lorenzo Celona; Luca Legato; Luisa Giaccone; Roberto Passera; Sara Muccio; Silvia Corcione; Sofia Zompi
|